AIMLF
AI/ML Innovations Inc.·Healthcare
0.02
6.050%(−0.00)
Market ClosedLast Updated: — ET
52W L: $0.0252W H: $0.09
AIMLF NEWS
accessnewswire.com
Mar 31
Neural Cloud Signs Reseller Agreement with European Digital Cardiac Monitoring Platform
Collaboration Expands Reach of MaxYield™ into Remote Heart Monitoring and Preventive Cardiology Applications TORONTO, ON / ACCESS Newswire / March 31, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) today announced that its wholly owned subsidiary, Neural Cloud Solutions Inc. ("Neural Cloud"), entered into a reseller agreement on March 25th, 2026 with a European-based digital health platform specializing in cloud-based ECG and heart rate variability (HRV) analytics. Under the agreement, the partner platform will integrate and resell Neural Cloud's MaxYield™ ECG signal-processing technology to its customers as either a standalone capability or as part of a bundled remote cardiac monitoring solution.
accessnewswire.com
Mar 27
AI/ML Innovations Inc. Announces Closing of First Tranche of Private Placement to Raise $950,000
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO, ON / ACCESS Newswire / March 27, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement (the "Offering") pursuant to which the Company has issued convertible debentures ("Debentures") in the aggregate principal amount of $950,000. The Debentures may be converted into units of the Company ("Units") at the option of the holder of the Debentures at any time at a conversion price of $0.05 per Unit, with each Unit being comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant").
accessnewswire.com
Mar 25
AIML Subsidiary NeuralCloud Enters Research Services Agreement with Baker Heart and Diabetes Institute to Support AI-Driven ECG Analysis
Agreement expands NeuralCloud's role in cardiovascular research and academic collaborations MaxYield™ platform to support heart rate variability analysis in post-exertional malaise research TORONTO, ON / ACCESS Newswire / March 25, 2026 / NeuralCloud Solutions Inc. ("NeuralCloud"), a subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is pleased to announce that on March 18th, 2026 the Company entered into a research services agreement with Dr. Kegan Moneghetti, MBBS (Hons) FRACP FCSANZ PhD, of the Baker Heart and Diabetes Institute, to provide AI-powered ECG signal processing in support of an ongoing cardiovascular research study. Under the agreement, NeuralCloud will apply its proprietary MaxYield™ ECG processing platform to existing ECG recordings supplied by the research team.
accessnewswire.com
Mar 12
AI/ML Innovations Inc. Announces Proposed Private Placement of Convertible Debentures
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO, ON / ACCESS Newswire / March 12, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it is proposing to complete a non-brokered private placement (the "Offering") pursuant to which the Company will issue convertible debentures ("Debentures") in the principal amount of up to $3,000,000. The Debentures may be converted into units of the Company ("Units") at the option of the holder of the Debentures at any time at a conversion price of $0.05 per Unit, with each Unit being comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant").
accessnewswire.com
Feb 24
Neural Cloud Enters Distribution Agreement with Intelimed to Expand into Latin America
Intelimed Appointed Exclusive Distributor in Chile and Non-Exclusive Distributor Across Latin America to lead commercialization in the region TORONTO, ON / ACCESS Newswire / February 24, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that on February 18th, 2026 its wholly owned subsidiary, Neural Cloud Solutions Inc. ("Neural Cloud"), entered into a distribution agreement with Intelimed.ai SpA ("Intelimed"), a Chile-based digital health solutions provider, to commercialize Neural Cloud's MaxYield™, CardioYield™, and Insight 360™ platforms in Latin America. Under the terms of the agreement, Intelimed has been appointed as exclusive distributor in Chile, and non-exclusive distributor throughout the rest of Latin America for Neural Cloud's cardiac software solutions.
accessnewswire.com
Feb 12
AIML Subsidiary NeuralCloud Signs Non-Binding Agreement with Movesense to Pilot AI-Powered ECG and Holter Reporting
Collaboration enables deployment of MaxYield™ and CardioYield™ into third-party health systems and clinic sites This pilot expands the Movesense collaboration to scale low-cost, AI-powered 1-lead ECG and Holter-style monitoring deployments TORONTO, ON / ACCESS Newswire / February 12, 2026 / NeuralCloud Solutions Inc. ("NeuralCloud"), a subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is pleased to announce that on February 11th, 2026 it entered into a non-binding agreement with Movesense, a global provider of medical-grade wearable sensing technology, to initiate a pilot program aimed at deploying AI-powered ECG and Holter reporting into real-world healthcare environments. Under the agreement, the parties will collaborate on a pilot deployment whereby NeuralCloud's software platforms are deployed via an existing Movesense client, within a third-party health system and affiliated clinics.
